Underage Use Prevention

November 7, 2019

In light of the studies released this week relating to the 2019 National Youth Tobacco Survey and Monitoring the Future survey, JUUL Labs’ CEO K.C. Crosthwaite announced that the company will immediately stop accepting orders from our retail partners for our Mint JUULpods in the U.S. and cease the sale of Mint JUULpods in the U.S. through our ecommerce site (JUUL.com). 

In making the announcement, Crosthwaite said: “These results are unacceptable and that is why we must reset the vapor category in the U.S. and earn the trust of society by working cooperatively with regulators, Attorneys General, public health officials, and other stakeholders to combat underage use. We will support the upcoming FDA flavor policy and will follow the PMTA process.”

As part of Crosthwaite’s review of JUUL Labs’ policies and practices, the company has already:

  • Refrained from lobbying the Administration on its draft flavor guidance. 
  • Suspended all broadcast, print, and digital product advertising in the U.S.
  • Stopped the sale of Mango, Creme, Fruit, and Cucumber JUULpods online in the U.S., pending FDA review. In November 2018, JUUL Labs stopped the distribution of these JUULpods to all of our traditional retail store partners. 
  • Announced a restructuring plan aimed at aligning the company’s organization and resources behind key priorities: earning trust by reducing and preventing underage use, investing in scientific research to ensure the quality of its PMTA application in the U.S., and expanding its commitment to develop new technology.
  • Ceased active support of Proposition C in San Francisco.

Crosthwaite and the leadership team will continue to review JUUL Labs’ policies and practices and will take appropriate actions as the company works to combat underage use and earn society’s trust.

As of today, JUUL Labs sells only Virginia Tobacco, Classic Tobacco, and Menthol JUULpods in the U.S. and it will not sell any others under any name unless they are first authorized by the FDA as part of the PMTA process.